Oct. 26 at 8:09 PM
$XNCR
Price (≈):
$13.22
Analyst targets (12-mo):
Bear
$6 • Base ~
$24.2 • Bull
$40.
(analyst consensus range).
Public intrinsic (SimplyWallSt / DCF):
≈
$25.7
Weighted benchmark = (6×25.73 + 4×6)/10 =
$17.84
Valuation risk = Entry − Weighted = −
$4.63 (negative → entry below conservative benchmark)
Potential reward = Bull − Entry =
$26.79
Reward / Risk = −5.79 (negative because denominator < 0 → you’re buying below weighted fair/bear mix; this is good in value terms).
Risk / Reward = −0.173 (same sign flip).
1-min checklist
Fundamentals: platform + partnerships; revenue growing recently.
Technical: improving RS and price momentum.
Verdict: Looks like a buyable biotech/biopharma growth name — market price sits below blended fair/bear benchmark; upside per analysts is sizable.
Bottom line:
Market price < blended fair/bear benchmark → analysts expect big upside; good value signal if you accept biotech execution risk.
#xncr #chatgpt #rickycelloanalisys
